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Introduction
Axillary lymph nodes receive the lymph from all 
areas of the breast. Involvement of axillary lymph nodes 
in breast cancer is an important factor in recurrence and 
survival of patients with breast cancer, and involvement of 
a large number of lymph nodes decreases the survival rate 
(McLaughlin et al., 2008; Yoshihara et al., 2013).
In patients with breast cancer, evaluation of axillary 
lymph nodes is an important part of staging and treatment 
of patients. Axillary lymph node dissection is a reliable 
procedure in staging and an effective method in regional 
control of the disease (Giuliano et al., 1994). As an effective 
and reliable method for evaluation of axillary lymph node 
in patients with early stage breast cancer, sentinel node 
biopsy has substituted axillary dissection since 1990 
(Murray and Given-Wilson, 1997; Veronesi et al., 2010).
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It should be noted that axillary lymphadenopathy 
without a proven malignancy can develop due to benign 
reactive reactions such as connective tissue disease 
and skin infections. Therefore, ultrasound can be used 
extensively for identification of breast and axillary 
pathologies in breast cancer patients (Patel et al., 2005; 
Schwab et al., 2010).
Diagnostic accuracy of ultrasound varies and depends 
on various factors including the operator’s skill and 
experience, the device type, and the limitation in standards 
(Ohuchi et al., 2009). According to the results of a study, 
the sensitivity and specificity of ultrasound for finding a 
pathologic lymph node are 63.3 and 84.6%, respectively. 
However, it has a low sensitivity level in detecting lymph 
node micro-metastases (Rezvani et al., 2018).
Moreover, the relationship between molecular 
subtypes of breast cancer has been raised as an important 
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factor in the prognosis and survival of patients with 
breast cancer. Numerous studies have shown that there 
is a relationship between breast cancer subtypes and 
axillary lymph node metastasis. One study has proven that 
luminal A and TNB patients have a lower risk for lymph 
node metastasis in comparison with luminal B and HER2 
patients (Yang et al., 2017).
Anita Mamtani studied the clinicopathologic status 
and axillary involvement in 701 stage I and stage II breast 
cancer patients and showed that there was no relationship 
between axillary lymph node involvement and triple 
negative breast cancer (Mamtani et al., 2016).
Kaptan Gullben et al. investigated the relationship 
between tumor subtypes including luminal A, HER2 
and luminal/HER2 and the extent of non-sentinel lymph 
node involvement in 104 breast cancer patients who had 
undergone axillary lymph node dissection. Univariate 
and multivariate evaluations showed that tumor size and 
the extent of lymph node involvement had a significant 
relationship with non-sentinel lymph node involvement, 
and that the extent of non-sentinel lymph node involvement 
was higher in luminal B and HER2 positive patients than 
in the triple negative patients. They concluded that tumor 
subtypes were an independent factor in the evaluation of 
non-sentinel lymph nodes in patients with positive sentinel 
lymph nodes (Lyman et al., 2014).
The present study performed sentinel lymph node 
biopsy in patients with T1T2 breast cancer, who had 
non-pathologic lymph node in clinical examination 
and ultrasound, to evaluate the pathologic results of 
axillary sentinel and non-sentinel lymph nodes and to 
determine the relationship between tumor subtype and 
the extent of involvement. In addition, it tried to predict 
the possibility of axillary lymph node involvement based 
on the ultrasound results and tumor subtype. According 
to the results of this study, could be sentinel biopsy used 
in patients with palpable and normal lymph node in 
ultrasound? Could they enjoy the benefit of sentinel biopsy 
and avoid axillary dissection merely due to palpability of 
the lymph nodes?
Materials and Methods
This study was performed on 102 patients with breast 
cancer who visited Imam Khomeini Hospital in Sari, 
Iran, from 2016 to 2018. The study was approved by and 
registered in the Cancer Research Center of Mazandaran 
University of Medical Sciences. Patients with a pathology 
report of invasive breast cancer and tumor size of less than 
5 cm whose axillary lymph nodes seemed non-pathologic 
in clinical examination and ultrasound were selected 
for sentinel lymph node biopsy. Patients’ demographic 
information and their pathologic reports before and after 
breast surgery as well as their axillary pathology reports 
were collected and analyzed.
The exclusion criteria were advanced breast cancer 
(stages III and IV), primary tumor size of larger than 5 cm, 
unwilling to participate in the study, DCIS patients and 
patients who received chemotherapy. Moreover, patients 
in whom sentinel lymph node was not detected during 
surgery, and axillary dissection was performed on them, 
were excluded from the study. All patients underwent 
bilateral axillary ultrasound by an experienced radiologist 
before the surgery and were selected for sentinel biopsy if 
the axillary lymph node was reactive and non-pathologic. 
A few hours before surgery, the radioisotope (technetium 
99) was injected by a nuclear medicine specialist into 
the peri areolar or peritumoral area and the patients were 
transferred to the operating room after lymphoscintigraphy 
and identification of the sentinel lymph node. The sentinel 
lymph nodes were identified before surgery using a gamma 
scanner and lymph nodes with more than 10% maximum 
radiation absorption in the injection site were removed and 
sent for frozen pathology to the Pathology Department. In 
the Pathology Department, lymph nodes smaller than 1 cm 
were incised with one incision and those larger than 2 cm 
with 2. Half of the lymph node was used for frozen section 
pathology. It was frozen at -30°C, stained with H&E, and 
microscopically examined by an experienced pathologist. 
After the initial evaluation, it was fixed in formalin for 
definitive pathologic evaluation. The remaining half of the 
lymph node was fixed in formalin for definitive pathology 
examination. If the frozen pathology report indicated 
that the lymph node was metastatic, axillary dissection 
was performed in the same stage. However, if the lymph 
node was negative and the final pathology report indicated 
metastatic involvement, two weeks after the first surgery 
a second delayed axillary surgery was performed and the 
lymph node was dissected. The final results concerning 
the numbers of involved sentinel and non-sentinel lymph 
nodes in patients who underwent the primary or delayed 
dissection of the axillary lymph nodes were studied and 
factors affecting the probability of involvement of axillary 
sentinel and non-sentinel lymph nodes were analyzed. 
In addition, immunohistochemistry (IHC) study was 
conducted on tumors, and the statuses of the estrogen, 
progesterone, HER2, and KI67 receptors, and of the triple 
negative receptors, were determined.
Statistical analysis
First, the type of data distribution was examined by 
plotting the histogram and performing the Kolmogorov-
Smirnov and/or Shapiro-Wilk test. Then the quantitative 
data were described through the calculation of mean, 
standard deviation, median and interquartile range. The 
qualitative data were described through calculation of 
frequencies and percentages. The relationship between 
qualitative variables was examined through Chi-square 
and/or Fischer exact tests. In addition, the odds ratio 
for each of the molecular subtypes in involvement of 
sentinel and non-sentinel lymph nodes was calculated by 
performing logistic regression.
The data were described and analyzed using IBM SPSS 
21. For all the statistical tests, the bilateral p-value <0.05 
was considered significant. 
Results
One hundred and two women with a mean age of 49 
years, range 30-79 years, having breast cancer with tumor 
size smaller than 4 cm and lymph nodes non-pathologic 
in ultrasound underwent axillary sentinel node biopsy. 
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The histopathology was invasive ductal cancer in 
97% of the tumors. All the patients had breast conserving 
surgery. A radioisotope (technetium 99) was injected 
preoperatively, the axillary sentinel lymph node was 
biopsied during the surgery and the frozen section was 
performed. The results of the frozen pathology was 
positive in 9.8% of the cases and these patients underwent 
axillary lymph node dissection. 53.3%of the patients had 
negative lymph node and hence did not undergo dissection 
during the surgery. Thirty-one point three of the results 
were false negative and 5.8%false positive. According to 
the final pathology report, 58.8% of the patients (including 
true negative sentinel node patients plus false positive 
sentinel node patients) had no lymph node involvement. 
In the final pathology report, 41.1% of lymph nodes 
(including true positive sentinel node patients plus false 
negative sentinel node patients) were involved (Table 1). 
All patients with a false negative frozen report 
underwent delayed axillary dissection. The sensitivity, 






Table 1. The Status of Axillary Sentinel Lymph Node in 
the Frozen and Final Pathology
Receptor positive SLN+ in frozen section SLN+ in final pathologic report
Kendall’s tau-b Spearman’s Rho Kendall’s tau-b Spearman’s Rho
Coefficient p-value Coefficient p-value Coefficient p-value Coefficient p-value
ER 0.183 0.066 0.183 0.065 0.199 0.046 0.199 0.045
PR 0.168 0.092 0.168 0.092 0.293 0.003 0.293 0.003
HER2
Ki67>14% 0.267 0.007 0.267 0.006 -0.029 0.771 -0.029 0.773
Triple negative 0.235 0.018
LVI 0.250 0.927 0.221 0.001
Figure 1. Results Related to Analysis of Diagnostic 
Accuracy of the Frozen Report in Comparison with 
the Golden Standard of the Final Pathology Report 
Performed Online with Diagnostic Test Calculator 
(https://ebm-tools.knowledgetranslation.net/calculator/
diagnostic/). The frozen section had the sensitivity and 
specificity of 24 and 90%, respectively, and the general 
diagnostic accuracy 0.431. The reason for the low 
sensitivity was the high number of false negative cases.
Table 2. Relationship between Tumor Receptors and Sentinel and Non-sentinel Axillary Lymph Nodes
Link function, Legit; a.This parameter is set to zero because it is redundant.
parameter Estimates 95% Confidence interval
Estimate Std.Error Wald df Sig. Lower Bound Upper Bound
Threshold [Nod Ratio Stat =1] 1.87 0.732 6.53 1 0.011 0.436 3.305
[ER=1] 0.663 1.128 0.345 1 0.557 -1.548 2.875
[ER=2] 0a . . 0 . . .
[PR=1] -0.137 1.038 0.017 1 0.895 -2.172 1.898
[PR=2] 0a . . 0 . . .
Location
[HER2=1] 0.413 0.53 0.607 1 0.436 -0.626 1.452
[HER2=2] 0a . . 0 . . .
[K167=1] 0.049 0.532 0.009 1 0.926 -0.994 1.092
[K167=2] 0a . . 0 . . .
Table 3. Presents the Result of Ordinal Regression for Evaluation of the Relationship between the Nodes Ratio 
(<25%, >25%) and the Different Receptors. As Can be Seen, the Receptor Status Cannot Predict NR
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were 24, 94, and 43%, respectively (Figure 1).
IHC study was conducted on the tumors and the 
statuses of hormone receptors including estrogen, 
progesterone, HER2, KI67and of triple negative receptors 
were determined. Seventy-five-point five percent were 
estrogen receptor positive, 70% progesterone receptor 
positive, 31.4% HER2 positive, 67.6% KI67<14% and 
14.7% triple negative. In this analysis, correlations 
between the positive status of hormone receptors and 
positive lymph node in the frozen section and the final 
pathology report were investigated. The results of 
Kendall’s tau-b coefficient and Spearman’s rho rank 
correlation coefficient are presented in Table 2. This Table 
shows that there was a statistically significant correlation 
between the positive status of ER and PR and involvement 
of the sentinel lymph node in final frozen pathology. In 
addition, the correlation between the status of KI67>14% 
and involvement of the sentinel lymph node in the frozen 
section was statistically significant.
The relationships between hormone receptors with 
axillary sentinel and non-sentinel lymph nodes were 
investigated in the patients. The results showed that the 
likelihood of either sentinel or non-sentinel lymph nodes 
involvement was higher in the estrogen and progesterone 
positive patients and lower in the triple negative patients. 
In addition, lymphovasuclar invasion was an effective 
factor in the involvement of axillary sentinel and 
non-sentinel lymph nodes (Table 2).
Discussion
Evaluation of axillary lymph nodes is an important 
part of breast cancer staging. It can be performed through 
clinical examination, ultrasound, the FNA procedure or 
a core needle biopsy. Sentinel node biopsy and axillary 
dissection are then carried out. Since the introduction 
of Halsted’s radical mastectomy, axillary dissection has 
been a successful method for local control and treatment 
of patients (Gülben et al., 2014). Sentinel lymph node 
biopsy is a method that can substitute axillary lymph node 
dissection in patients with early stage breast cancer who 
have non-palpable lymph nodes. It is currently a standard 
method with fewer complications for evaluation of lymph 
node involvement in this group of patients (Rao et al., 
2013; Lyman et al., 2014).
Results of studies in recent years have changed 
the management of patients with low tumor burden in 
axillary lymph node involvement so that treatments have 
increasingly tended to be less invasive due to the early 
and delayed complications of axillary treatment. For 
example, the ZOO11 trial recommended that axillary 
dissection be omitted in patients who were candidates 
for breast conserving surgery and had less than 2 lymph 
nodes involved in the sentinel lymph node evaluation 
(Giuliano et al., 2011)
Evaluation of axillary lymph nodes in early stage 
breast cancer patients with clinically negative lymph 
node is performed through sentinel node biopsy (Keshtgar 
and Ell, 2002; Veronesi et al., 2003; Zhou et al., 2011). 
However, lymphadenopathy may have reactive causes 
such as inflammatory diseases and skin infections, and 
preoperative ultrasound can report the probability of 
pathologic or reactive causes of lymph nodes based on 
characteristics of lymph nodes such as their shape (oval, 
round) and cortex thickness (Lim et al., 2004; Muttarak 
et al., 2004). However, ultrasound has limited diagnostic 
power and cannot identify micro-metastases (Chu et al., 
1999).
Sentinel node biopsy is the standard procedure in 
patients with clinically negative lymph nodes, and in 
cases of positive sentinel node it is followed by dissection. 
However, 40-70% of these patients have no metastasis in 
the non-sentinel lymph nodes (Chu et al., 1999; Hwang et 
al., 2003; Nos et al., 2003)and axillary dissection has the 
negligible therapeutic effect for them (Nos et al., 2003; 
Moghaddam et al., 2010).
Breast cancer is a heterogeneous tumor with different 
molecular subtypes, clinical manifestations, and response 
to treatment. Numerous studies have investigated the 
relationship between breast cancer subtypes and axillary 
lymph node involvement. Geok Hoon Lim et al. tried to 
identify patients with high node burden to avoid sentinel 
node biopsy for them. They investigated 1298 T1T2N0 
patients and found that sentinel node biopsy could be 
avoided and axillary dissection be performed in patients 
with ≤4 abnormal lymph nodes in ultrasound (Hirko et 
al., 2013; Lim et al., 2019)
Another study revealed that there was a relationship 
between breast cancer subtypes and axillary metastasis, 
and that luminal A and TNB patients had a lower risk 
for node involvement than luminal B and HER2 patients 
(Yang et al., 2017).
In addition, a study in 2014 showed that luminal 
B patients (either HER2+ or HER2-) had a strong 
relationship with node involvement, and that triple 
positive and triple negative breast cancer exhibited the 
highest and lowest probability of axillary lymph node 
involvement, respectively (Si et al., 2014).
Öz et al., (2016) studied 110 sentinel node positive 
patients who underwent axillary dissection 101 of 
whom had up to 2 involved lymph nodes and 32 showed 
non-sentinel lymph node involvement. Univariate and 
multivariate analyses indicated that lymphovascular 
invasion and positive ER and PR, HER2 and KI67>14% 
receptors were associated with higher involvement of 
non-sentinel lymph nodes.
In a study by Ahmed (2016), HER2 was introduced 
as a potent prognostic factor in lymph node metastasis 
in breast cancer. In this study, the primary breast cancer 
tumors of 317 patients were investigated for estrogen, 
progesterone and HER2 receptors using IHC staining. A 
relationship was found between these markers and axillary 
lymph node metastasis by employing statistical methods. 
They noticed that ER, PR, and HER2 were expressed 
in 35.7, 73.2 and 19.9% of the tumors, respectively. In 
addition, the tumor size and grade had a direct relationship 
with HER2 and inverse relationships with PR and ER. 
Univariate analysis revealed that HER2 had a direct 
relationship with axillary lymph node metastasis.
This study concluded that lymph nodes were palpable 
in some breast cancer patients but they were motile, small, 
and soft and non-pathologic and reactive in ultrasound 
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(nodes were smaller than 2 cm, normal cortex thickness 
or were reactive and oval-shaped with normal fat), 
lymph node involvement was less likely in them, and 
they benefited from sentinel node biopsy. These patients 
were candidates for sentinel lymph node biopsy and, if 
the biopsy result was positive, they underwent axillary 
dissection. The extent of involvement of axillary sentinel 
and non-sentinel lymph nodes was then investigated 
and the relationship between the status of the receptors 
including ER, PR, HER2, TN, and KI67 and the 
probability of lymph node involvement was evaluated to 
find predictive factors that could predict the probability 
of lymph node metastasis based on ultrasound findings 
and on the status of tumor receptors.
More than 50 percent (53%) of the patients were with 
negative sentinel lymph nodes that were not dissected and 
9.8%% of the patients were sentinel lymph node positive 
in frozen section. In some studies on rate of false negative 
sentinel biopsy in clinically lymph node negative patients 
the reported rate of false negative frozen was 10 to 60%, 
but most of such studies have reported rates of 15-20% 
(Nos et al., 2003; Moghaddam et al., 2010; Hirko et al., 
2013). In the present research, the rates of false negative 
sentinel and false positive sentinel were 31.3 and 5.8%, 
respectively, and the diagnostic accuracy of frozen section 
was 43%.  Forty seven percent of patients underwent 
axillary lymph node dissection in 21% of whom the extent 
of tumor burden (Node ratio or NR, which is the ratio of 
the number of metastatic lymph nodes to the total number 
of dissected) was ≤ 25% and in 79% it was more than 
25% (Table 3). In fact, the majority of the patients had 
micro-metastatic involvement with less than 3 involved 
nodes. The probability of involvement was higher in 
estrogen and progesterone positive patients (p<0.003). In 
addition, the likelihood of non-sentinel node involvement 
was higher in patients with KI67>14% (p<0.006) and also 
in patients with lymphovascular invasion (p<0.001), but 
the probability of non-sentinel node involvement was 
lower in triple negative patients (p<0.018). No specific 
and statistically strong relationship was found between 
nodal ratio and receptor expression.
The results of many studies on the relationship 
between breast cancer subtypes and axillary lymph node 
involvement have been contradictory. Some have reported 
higher likelihood of lymph node involvement in receptor 
positive patients whereas others have reported higher 
probability of lymph node involvement in triple negative 
patients. Therefore, this issue needs further research.
The present study evaluated the relationship between 
hormone receptors and involvement of axillary lymph 
nodes, and then used this predictive power for selecting 
T1T2 patients (who had palpable lymph nodes but were 
clinically non-pathologic and had no abnormal ultrasound) 
as candidates for sentinel biopsy instead of lymph node 
biopsy using COR or FNA. Finally, it tried to determine 
how likely it was to find non-sentinel lymph node 
involvement in the patients with false negative sentinel 
results.
Our results indicated that, if this group of patients 
underwent sentinel biopsy, the rates of false negative 
and false positive would be higher. However, according 
to recent trials such as ZOO11 and the AMAROSE, the 
likelihood of non-sentinel lymph node involvement is 
lower in patients with less than 3 involved nodes in the 
final pathology report  who also have the receptor negative 
criterion (K167<14) and are LVI negative. Therefore, it is 
possible to avoid axilla dissection in these patients and to 
locally control axilla by using radiotherapy.
Study of the relationship between tumor subtypes with 
estrogen and progesterone positive receptors and patients 
with KI67>14% showed that the likelihood of sentinel 
and non-sentinel lymph node involvement was higher, 
but this relationship lacks considerable predictive power 
because of the small sample size. However, our study 
showed that the majority of patients who were deprived 
of sentinel evaluation merely based on clinically palpable 
lymph node had no pathologic lymph node involvement in 
the sentinel nodes or in the non-sentinel nodes. Therefore, 
they suffered from complications of axillary dissection.
We suggest that a study with a larger sample size be 
conducted to find a way for identifying those patients who 
are appropriate candidates for sentinel biopsy in whom 
there is less likelihood of lymph node involvement.
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